FindTrial
Sign In

Study for Cytotoxicity and Immunoregulatory Function of Highly Actived NK Cells in the Treatment of AIDS

Study for Cytotoxicity and Immunoregulatory Function of Highly Actived NK Cells in the Treatment of AIDS

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021196
Enrollment
Unknown
Registered
2019-02-01
Start date
2019-02-01
Completion date
Unknown
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS

Interventions

Control group:Antiretroviral therapy
Experimental group:Antiretroviral therapy+HANK cell therapy

Sponsors

Tianjin Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Aged 25 to 40 years; 2. HIV-1 infected patients who started antiviral therapy between January 1, 2015 and December 31, 2016; 3. The number of CD 4+ T cells in the peripheral blood was less than 200 cells/ul after antiviral treatment for more than half a year. 4. In the course of antiviral therapy, plasmaViral load (HIV-1 RNA) was lower than 20CP/ml and NK cell reinfusion therapy was accepted or not. 5. Compliance was good. As of December 31, 2018, the effective follow-up time (with CD4 test results) exceeded 2 years.

Exclusion criteria

Exclusion criteria: 1. Low complianace; 2. Antiviral resistance.

Design outcomes

Primary

MeasureTime frame
CD4;CD4/CD8 T cell ratio;Cell factor;—

Secondary

MeasureTime frame
Blood routine;Liver function;Renal function;—

Countries

China

Contacts

Public ContactYu Cao

Tianjin Second People's Hospital Affiliated to Nankai University

cyu1987@163.com+86 022 27426301

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026